1. Home
  2. EOD vs VCRE Comparison

EOD vs VCRE Comparison

Compare EOD & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

N/A

Current Price

$5.98

Market Cap

272.6M

Sector

Finance

ML Signal

N/A

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$10.61

Market Cap

271.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EOD
VCRE
Founded
2007
2000
Country
United States
Sweden
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
272.6M
271.7M
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
EOD
VCRE
Price
$5.98
$10.61
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $24.27
AVG Volume (30 Days)
★ 112.2K
16.6K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 9.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$38.94
Revenue Next Year
N/A
$694.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.51
$7.88
52 Week High
$6.74
$14.01

Technical Indicators

Market Signals
Indicator
EOD
VCRE
Relative Strength Index (RSI) 34.89 50.38
Support Level $5.51 $8.83
Resistance Level $6.26 $11.78
Average True Range (ATR) 0.12 0.40
MACD -0.02 0.02
Stochastic Oscillator 4.76 47.26

Price Performance

Historical Comparison
EOD
VCRE

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: